Which therapies are the most effective to prevent the progression of autosomal dominant polycystic kidney disease?
There is considerable interest in innovative treatments for adult polycystic kidney disease, in particular those treatments that might interrupt the biological processes that lead to cyst formation and kidney failure. It is important, therefore, to have good evidence of the effects of these treatments and, in a July 2015 Cochrane Review, Davide Bolignano from Reggio Calabria in Italy and colleagues examined the relevant studies to assess the effects on patient outcomes. Here ’s Davide to tell us more. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - September 5, 2016 Category: Journals (General) Authors: Cochrane Source Type: podcasts
Tolvaptan and Liver Damage Warnings: Tip of the Iceberg?
Jeffrey Berns talks about the FDA warnings concerning liver damage with the use of tolvaptan, recently approved for polycystic kidney disease. (Source: Medscape Nephrology Podcast)
Source: Medscape Nephrology Podcast - February 21, 2013 Category: Urology & Nephrology Authors: Medscape Source Type: podcasts
Tolvaptan: A New Weapon for a Tough Kidney Disease
This F1000 commentary reports on a study whose findings support the use of tolvaptan to slow the progression of autosomal dominant polycystic kidney disease (ADPKD). (Source: Medscape Nephrology Podcast)
Source: Medscape Nephrology Podcast - February 14, 2013 Category: Urology & Nephrology Authors: Medscape Source Type: podcasts
Tolvaptan: Exciting Progress for Polycystic Kidney Disease
In this international Skype conversation, Lynda Szczech and Donal O’Donoghue provide in-depth guidance on the current research and use of tolvaptan in autosomal dominant polycystic kidney disease. (Source: Medscape Family Medicine Podcast)
Source: Medscape Family Medicine Podcast - January 16, 2013 Category: Primary Care Authors: Medscape Source Type: podcasts
